New biomarkers could prevent unnecessary pancreatic surgery
NCT ID NCT06574373
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 34 times
Summary
This study looks for biological markers (biomarkers) that can tell the difference between harmless and dangerous pancreatic cysts called IPMNs. Some IPMNs can turn into pancreatic cancer, but current methods to predict this are not very accurate. Researchers will study tissue and blood samples from 3,600 people to find molecular clues that could help doctors decide who needs surgery and who can safely wait and watch.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPMN, PANCREATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Gemelli
RECRUITINGRoma, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IRCCS Fondazione Policlinico Universitario A. Gemelli
NOT_YET_RECRUITINGRome, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.